A Trends in Immunology opinion article by 31 KOL endorses the development of AMY-101 for the treatment of periodontitis:
“We posit that C3-targeted intervention might represent a novel and transformative host-modulation therapy meriting further investigation in Phase III clinical trials for the treatment of periodontitis.”
Hajishengallis G, Hasturk H, Lambris JD, Contributing authors. (2021). C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends Immunology 42: 856-864.